Emcure Pharmaceuticals has acquired the remaining 12.05% stake in Gennova Biopharmaceuticals, making the Maharashtra based biotechnology company a wholly owned subsidiary. The move is aimed at strengthening Emcure’s presence in the fast-growing biologics and biosimilars segment while simplifying the company’s ownership structure under its One Emcure strategy..

Emcure Pharmaceuticals 已收购 Gennova Biopharmaceuticals 剩余的 12.05% 股权，使这家位于马哈拉施特拉邦的生物技术公司成为其全资子公司。此举旨在加强 Emcure 在快速增长的生物制剂和生物类似药领域的布局，同时在其 “One Emcure” 战略下简化公司的所有权结构。

As part of the restructuring, Samit Mehta has been appointed Chief Executive Officer (CEO) of Gennova, leading the company into its next phase of growth. The leadership transition also marks the conclusion of Dr. Sanjay Singh’s nearly 20-year tenure at Gennova, during which the company emerged as one of India’s leading biotechnology innovators..

作为重组的一部分，萨米特·梅塔（Samit Mehta）被任命为Gennova的首席执行官（CEO），带领公司进入下一个增长阶段。此次领导层交接也标志着桑杰·辛格博士（Dr. Sanjay Singh）在Gennova近20年任期的结束，在他的领导下，该公司已成为印度领先的生物技术创新者之一。

According to Emcure, the acquisition aligns with its long-term strategy of consolidating biologics operations under a unified structure to enhance operational efficiency, accelerate innovation and strengthen its global competitiveness in advanced therapeutics.

据Emcure称，此次收购符合其长期战略，即将生物制剂业务整合到统一架构下，以提高运营效率、加速创新并增强其在先进治疗领域的全球竞争力。

Commenting on the development, Satish Mehta, Managing Director & CEO of Emcure Pharmaceuticals, said the acquisition simplifies Gennova’s ownership, sharpens its strategic focus and positions the company for accelerated growth in biologics and biosimilars under Samit Mehta’s leadership.

Emcure Pharmaceuticals 董事总经理兼首席执行官 Satish Mehta 在评论此次发展时表示，该收购简化了 Gennova 的所有权结构，强化了其战略重点，并使公司在 Samit Mehta 的领导下，为在生物制品和生物类似药领域实现加速增长做好了准备。

The biologics and biosimilars market is witnessing rapid global expansion, driven by increasing demand for targeted therapies to treat cancer, autoimmune diseases and other chronic conditions. Industry experts believe the consolidation will enable Emcure to strengthen research and development, scale manufacturing capabilities and expand its presence in domestic and international markets..

生物制剂和生物类似物市场正在经历快速的全球扩张，这得益于对用于治疗癌症、自身免疫性疾病和其他慢性疾病的靶向疗法需求的不断增长。行业专家认为，此次整合将使Emcure公司加强研发，扩大生产能力，并拓展其在国内外市场的布局。

The acquisition underscores Emcure Pharmaceuticals’ commitment to building a stronger biotechnology portfolio and reinforcing India’s position as a global hub for biopharmaceutical innovation, advanced biologics and affordable biosimilar development.

此次收购凸显了Emcure制药公司致力于构建更强大的生物技术产品组合，并巩固印度作为全球生物制药创新、先进生物制剂和可负担生物类似物开发中心的地位。